Circulating Chlamydia Trachomatis Antigens in Subjects With Alzheimer's Disease

Steven Lehrer1, Peter H Rheinstein2

  • 1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, U.S.A.; steven.lehrer@mssm.edu.

In Vivo (Athens, Greece)
|October 29, 2022
PubMed
Abstract

Insights

Chlamydia trachomatis PorB antigen levels were higher in Alzheimer's disease (AD) patients, suggesting a role for chlamydial infections in AD pathogenesis. This finding supports the link between C. pneumoniae and AD development.

Area of Science:

  • Neuroscience
  • Infectious Disease Epidemiology

Background:

  • Chlamydia pneumoniae (C. pneumoniae) is a suspected contributor to Alzheimer's disease (AD) pathogenesis.
  • Bacterial bodies have been found in AD brain tissue, but not in healthy brains.
  • Mouse studies indicate C. pneumoniae can enter the central nervous system via nasal pathways, promoting beta-amyloid deposition.

Purpose of the Study:

  • To investigate the association between chlamydial infection markers and Alzheimer's disease using UK Biobank data.
  • To explore the relationship between C. trachomatis PorB antigen levels and AD, using C. trachomatis as a surrogate for C. pneumoniae due to cross-reactivity.

Main Methods:

  • Utilized UK Biobank data, including Chlamydia trachomatis (C. trachomatis) PorB antigen levels (UKBB field 23037) and ApoE genotypes (rs429358, rs7412).
  • Employed logistic regression to analyze the association between PorB antigen levels and AD, controlling for age, sex, education, and ApoE genotype.

Main Results:

  • Significantly higher PorB antigen levels for C. trachomatis were observed in subjects with AD (p=0.007).
  • Each unit increase in sqrt PorB antigen for C. trachomatis was associated with a 1.156 increased odds of AD (p=0.004).
  • PorB antigen levels showed no significant relationship with ApoE genotype (p=0.783).

Conclusions:

  • Elevated C. trachomatis PorB antigens in AD patients support the hypothesis that C. pneumoniae-induced inflammation contributes to AD development.
  • Bacterial or viral infections may trigger the reactivation of dormant pathways implicated in AD.
  • Further research is needed to elucidate the role of chlamydial infections in Alzheimer's disease.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
626
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
246
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
77